home / stock / mnpr / mnpr news

MNPR News and Press, Monopar Therapeutics Inc. From 03/28/23

Stock Information
Company Name: Monopar Therapeutics Inc.
Stock Symbol: MNPR
Market: NASDAQ
Website: monopartx.com
Menu
MNPR MNPR Quote MNPR Short MNPR News MNPR Articles MNPR Message Board
Get MNPR Alerts

News, Short Squeeze, Breakout and More Instantly...
MNPR - Monopar stock crashes ~50% as Validive program gets axed after trial failure

2023-03-28 05:57:36 ET Monopar Therapeutics' ( NASDAQ: MNPR ) is discontinuing the active development of Validive after the drug did not meet the required efficacy to prevent severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) in a phase 2b/3 trial ca...
MNPR - Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis

WILMETTE, Ill., March 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced complet...

MNPR - Monopar Therapeutics GAAP EPS of -$0.22 misses by $0.02

2023-03-23 09:12:28 ET Monopar Therapeutics press release ( NASDAQ: MNPR ): Q4 GAAP EPS of -$0.22 misses by $0.02 . Cash, cash equivalents and short-term investments as of December 31, 2022, were $13.1 million. Monopar expects that its current funds will be sufficien...

MNPR - Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments

Validive ® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next Week Camsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m 2 ) WILMETTE, Ill., March 23, 2023 (GLOBE NEWSWIRE) -...
MNPR - Monopar to Present at the 35th Annual Roth Conference

WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson...

MNPR - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time to start the day with a look at the biggest pre-market stock movers traders need to know about on Monday! Moving stocks this morning are earnings reports, clinical tria...

MNPR - Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials

WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced an expansion of their radiopharmaceutical collaboration along with a new radiolabeled MNPR-1...
MNPR - Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin

WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the foll...

MNPR - Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT

WILMETTE, Ill., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it is planning to ...

MNPR - Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2

WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the positive recommenda...
Previous 10 Next 10